Save money and time, get standardized analysis. One of the broadest coverage of EU markets. Our key value proposition is provision of high quality pan-European support
Analyses from the same vendor for 19 different EU countries
We will help you navigate through the challenges of reimbursement and funding for medical devices and in-vitro diagnostics in Europe
MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry
MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry
Scope
Coding, payment mechanism, reimbursement tariffs, pathway to create or improve reimbursement situation
Project-based on-demand work or >95 off-the-shelf syndicated reports
Countries
19 EU
Availability
Mixed
Scope
Seminars on introduction into market access for medical devices and IVD tests, seminars on reimbursement systems in individual countries (>70 reports)
Syndicated analytical reports on the topics of HTA, innovation funding, reimbursement of health apps
Countries
19 EU
Availability
Off-the-shelf
Scope
Subscription service with email alerts about initiated or published health technology assessments of medical devices and in-vitro diagnostic tests from 56 HTA organizations globally
Countries
24 countries globally
Availability
On-demand
Scope
Subscription service with email alerts about key reimbursement developments for medical devices and in-vitro diagnostic tests (codes, DRG system, coverage decisions, innovation funding) from more than 30 organizations in Europe
Countries
14 EU
Availability
On-demand
Scope
Procedure code and DRG applications, other reimbursement applications in selective markets
Countries
Nordics and Russia
Availability
On-demand
Why us?
Pharma approach is put aside
Work with a company truly specialized in medical devices and diagnostics. Benefit from our topical knowledge from hundreds of projects
Getting results instantly (reports) or within 4-8 weeks (services)
Make business decisions quickly
15 out of top-30 companies choose MTRC for reimbursement support
Work with a provider who understands the industry’s needs. We served more than 108 clients over the last three years
More than 400 accomplished projects
Work with a provider who has experience in your field. We pay a lot of attention to maintain a good quality of services, including >300 internal instructions, regular quality management meetings, strict onboarding and training procedures
Team of 15 full-time employees in 6 countries
Unlike companies with an affiliate model, we do most services with in-house analysts ensuring greater quality, lower cost and predictable outcomes
MTRC is a thought leader in the field of European Med Tech reimbursement
MTRC has unique insights into market access through its various activities, including annual syndicated reports on the topics of HTA, innovation funding, reimbursement of digital health, comprehensive newsletter services, unparalleled educational platform and others
To stay up-to-date, we daily monitor developments of reimbursement systems in Europe
Subscribe to our newsletter to get updates every 2nd week
Only less than 10% of the news is reported in the free-of-charge newsletter. Access our paid services "HTA Alerts" and "Reimbursement Alerts" to get full, customized reports from more than 90 reimbursement and HTA organizations globally. Free first issues of both newsletters are available for download
12 Jul 2021
MTRC released an update of the syndicated report on reimbursement decisions for IVD tests in 5 EU countries (Belgium, France, Germany, the Netherlands, and Switzerland). The updated report covers 3-year period of 2018-2020. Broader coverage gives a better understanding of the activity of the reimbursement organizations.
29
Jul 2021
In early July 2021, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, nineteen health apps are now available at the DiGA Directory.
28
Jul 2021
On July 01, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering March 21, 2021 - June 21, 2021). One new Clinical Commissioning Policy related to radiotherapy was published. Three new policies were added to the work program; however, all related to pharmaceuticals only. The status of ongoing policies was updated as well.
27
Jul 2021
On June 30, 2021, the Interterritorial Council of the National Health System has approved the agreement of the Committee of designation of Centers, Services, and Reference Units (CSUR) for the designation of 21 new CSUR for seven pathologies, including ophthalmological diseases and the renovation of designation of six CSUR for adults with congenital heart disease.
26
Jul 2021
The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.
Our two core services are the provision of off-the-shelf and on-demand reimbursement analysis and the development of reimbursement strategy for medical devices in 19 European countries
| Analysis | |
Reimbursement
|
National fundingWillingness to pay for technology, based on:
|
| Strategy |
Reimbursement strategyPathway to get reimbursement:
|
Check our specific propositions for: Med Tech industry, IVD industry, Investors
Our services cover 19 European countries, including Austria, Belgium, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, Switzerland and Turkey
We provide services for major types of medical technologies
|
Implantable devices |
Interventional procedures |
Non-interventional procedures |
In-vitro diagnostic tests |
Medical aids |
|
Our analytical team has worked on hundreds of reimbursement projects within different clinical and technological areas, including heart valve replacement, minimally invasive and open heart surgery, coronary, cerebral and peripheral stenting, coronary diagnostic and imaging techniques (fractional flow reserve, intravascular ultrasound), coronary, cerebral and peripheral vascular thrombectomy, implantable and extracorporeal ventricular assist devices, clinic- and home-based dialysis, extracorporeal membrane oxygenation, apheresis, obesity surgery, hernia and reconstruction surgery, tissue products and skin reconstruction surgery, negative wound pressure therapy and medical bandages, neurostimulators for different indications, cell therapy, rehabilitation devices, devices for minimally invasive and open spine surgery, embolization procedures, glucose monitoring, use of fusidial markers, radiotherapy, endoscopy and more
|
Confidence in results
We have established numerous procedures and services to ensure the high relevance and precision of our analysis in order to successfully guide your business decisions:
- Standard Operating Procedures and Work Instructions
- Access to official coding and DRG manuals, tariff lists and grouping software
- A team comprised of experienced Clinical Coders with a medical background
- Quick access to health authorities to address uncertainties
- Ongoing research program to get insights from payer and provider interviews
- All reports are reviewed by the CEO before release
Check out our database of the off-the-shelf reimbursement reports for medical technologies in 11 European countries
Released reports:
|
Ongoing reports:
|